Dominari Holdings Inc. (DOMH) - Dilution Analysis

10-K filing | 22.6M shares outstanding

10-Q filing | 14.6M shares outstanding

S-3 filing: Resale of up to 13,940,546 shares of common stock by selling stockholders.

10-K filing | 14.6M shares outstanding

8-K filing: Dominari Holdings Inc. entered into agreements for a registered direct offering and a concurrent private placement, selling shares and warrants to accredited investors. They also entered advisory agreements to issue shares for advisory services. ($13.45M proceeds)

S-3 filing: Dominari Holdings Inc. files an S-3 registration statement to offer common stock, preferred stock, subscription rights, and debt securities for total gross proceeds of up to $100,000,000.

10-Q filing | 6.3M shares outstanding

10-Q filing | 6.1M shares outstanding

10-Q filing | 6.0M shares outstanding

10-K filing | 5.9M shares outstanding

10-Q filing | 5.3M shares outstanding

10-Q filing | 4.8M shares outstanding

10-Q filing | 4.6M shares outstanding

10-K filing | 4.8M shares outstanding

10-Q filing | 5.3M shares outstanding

8-K filing: Aikido Pharma Inc.'s subsidiary, Dominari Financial Inc., entered into an Amended and Restated Services Agreement with Kyle Wool, where he will serve as a consultant and later as CEO, with potential stock bonus awards tied to revenue targets, subject to stockholder approval of the 2022 Equity Incentive Plan. ($3.0M proceeds)

10-Q filing | 5.3M shares outstanding

8-K filing: Stock split 1-for-17 | Outstanding: 89,293,446 → 5

10-Q filing | 89.3M shares outstanding

10-K filing | 89.3M shares outstanding

8-K filing: Aikido Pharma, Inc. entered into a Securities Purchase Agreement to issue and sell Series O and Series P Redeemable Convertible Preferred Stock and intends to propose a reverse stock split at its 2022 annual meeting of shareholders with a ratio ranging from 5-1 to 30-1. ($20.95M proceeds)

10-Q filing | 89.7M shares outstanding

10-Q filing | 89.7M shares outstanding

10-Q filing | 89.5M shares outstanding

8-K filing: AIkido Pharma, Inc. amended its exclusive patent license agreement with Silo Pharma, converting 500 shares of Series M Convertible Preferred Stock into 625,000 restricted shares of common stock, effective January 5, 2021.

10-K filing | 34.9M shares outstanding

8-K filing: AIkido Pharma Inc. completed a public offering of 46,875,000 shares of common stock at a price of $1.60 per share, with gross proceeds of approximately $75,000,000, and granted the underwriter warrants to purchase up to 3,750,000 shares of common stock at an exercise price of $2.00 per share. ($75.0M proceeds)

8-K filing: Aikido Pharma, Inc. entered into an exclusive patent license agreement with Silo Pharma Inc. and issued 500 shares of Series M Convertible Preferred Stock as consideration for the license. ($0.5M proceeds)

10-Q filing | 34.9M shares outstanding

S-1/A filing: This is an S-1/A filing for a best-efforts offering of common stock, with H.C. Wainwright & Co., LLC as the exclusive placement agent.

S-1 filing: This is an S-1 filing for a best-efforts offering of common stock. The public offering price per share will be determined at the time of pricing and may be at a discount to the then-current market price.

10-Q filing | 34.9M shares outstanding

8-K filing: Certain owners of AIkido Pharma Inc. sold 1,512,465 shares of common stock to a healthcare-dedicated investment fund pursuant to a Stock Purchase Agreement.

S-3/A filing: The Registrant is registering an indeterminate aggregate principal amount and number of securities of each identified class of securities up to a proposed aggregate offering price of $100,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issuable upon conversion, redemption, repurchase, exchange, or exercise of any securities registered hereunder, including under any applicable anti-dilution provisions.

S-3/A filing: This is an S-3/A filing for a shelf registration of various securities including common stock, preferred stock, purchase contracts, warrants, subscription rights, depository shares, and debt securities up to an aggregate offering price of $100,000,000.

10-Q filing | 34.9M shares outstanding

S-3 filing: The Registrant is registering an indeterminate aggregate principal amount and number of securities of each identified class of securities up to a proposed aggregate offering price of $100,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issuable upon conversion, redemption, repurchase, exchange, or exercise of any securities registered hereunder, including under any applicable anti-dilution provisions.

8-K filing: AIkido Pharma Inc. completed a registered direct offering of 14,000,000 shares of common stock at $1.00 per share, resulting in gross proceeds of $14.0 million. ($14.0M proceeds)

8-K filing: Spherix Incorporated completed a registered direct offering of 2,090,909 shares of common stock at $2.75 per share, resulting in gross proceeds of approximately $5.75 million. ($5.75M proceeds)

8-K filing: Spherix Incorporated entered into a Securities Purchase Agreement to issue and sell 3,245,745 shares of common stock and common warrants, along with 3,897,113 pre-funded warrants, in a registered direct offering, resulting in gross proceeds of approximately $7.5 million before deducting fees and expenses, which closed on March 5, 2020. ($7.5M proceeds)

S-1/A filing: S-1/A filing represents warrants issuable to H.C. Wainwright & Co., LLC to purchase common stock equal to 8.0% of the common stock and pre-funded warrants offered, at an exercise price equal to 125% of the public offering price.

S-1/A filing: This S-1/A filing, dated February 26, 2020, relates to an offering of up to 3,073,770 shares of common stock, common warrants to purchase up to 3,073,770 shares of common stock, and pre-funded warrants to purchase up to 3,073,770 shares of common stock.

8-K filing: Spherix Incorporated announced the record date for the distribution to stockholders of 70,000 shares of common stock of Hoth Therapeutics, Inc., with each Spherix stockholder entitled to receive one share of Hoth common stock for every seventy shares of Spherix common stock held as of March 4, 2020.

10-K filing | 4.8M shares outstanding